ClinicalTrials.gg
RecruitingNCT06582680Updated Nov 20, 2026

Aging, Beta Blockers, and Thermoregulatory Responses

A Phase 4 interventional study of Ambient Heat in Heat Stress and Aging, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Texas Southwestern Medical Center · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Heat Stress Disorders with a site in United States — 11 open to participants now, 13 under way, none of them phase 3. Heat Stress Disorders · United States.

Planned enrollment
19th of 27
22 · median 24
Started
2024
with 4 others
Phase 4
2 of 33
2 open now
Primary completion
2027-09
later than 9 of 12 live
Registered
19th of 33
by date
Lead sponsor
2 of 33
University of Texas Southwestern Medical Center

Among the 33 studies in Heat Stress Disorders with a site in United States, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2024, is one of 2 in phase 4, reaches primary completion later than 9 of the 12 other live ones, and was the 19th registered.

Heat Stress Disorders

118 studies on the registry are indexed under Heat Stress Disorders; 42 are open to participants now.

Browse Heat Stress Disorders studies →

Open to participants now

11 of the 33 studies in Heat Stress Disorders with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Heat Stress Disorders studies recruiting now, 8 (27%) set no upper age limit and 18 (60%) stop at 75 or younger; 6 take children under 18; 22 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Heat Stress Disorders with a site in United States, or all of them as a file.
02

Study summary

This study will test the hypothesis that the drugs propranolol and metoprolol will result in greater increases in core body temperature during 3 hours of extreme heat exposure in older adults.

Read the detailed description

Older individuals are more likely to die or become ill during heat waves. During the 1995 Chicago heat wave, there was 35% increase in hospital admissions for individuals older than 65 years of age. Moreover, adults over the age of 65 have a heat-related death rate that is more than double any other age group. Therefore, with an increasing elderly population that is expected to rise by 60% (to 78 million) by 2035, the causes of this excess mortality must be understood to better protect the ageing United States population. It is notable that selective and non-selective beta blocker drugs are commonly prescribed to older individuals with cardiovascular diseases. In younger individuals exposed to a heat stress, beta blocker administration reduced whole-body sweat rate and skin blood flow responses resulting in greater increases in core body temperature. Notably, nothing is known regarding the effects of beta blockers on thermoregulatory responses during heat exposure in older individuals.

This project will evaluate core body temperature responses to selective and non-selective beta blocker drugs during simulated heat wave exposure in older individuals.

03

Conditions studied

  • Heat Stress
  • Aging

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy and free of any significant medical problems
  • Normal resting
  • 65+ years of age
  • Controlled cholesterol of less than 200 mg/dl
  • Controlled blood pressure of less than 140/90 mmHg

Exclusion criteria

Exclusion Criteria:

  • Known diseases or other chronic conditions requiring regular medical therapy including cancer, diabetes, neurological diseases, uncontrolled hypertension, and uncontrolled hypercholesterolemia
  • Serious abnormalities detected on routine screening
  • Taking prescribed medications or over-the-counter medications that have known influences on either cardiac function or sweating
  • Current smokers, as well as individuals who regularly smoked within the past 3 years
  • ≥31 kg/m2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Placebo, then Propranolol, then Metoprolol

    Other: Ambient Heat

  • Experimental
    Placebo, then Metoprolol, then Propranolol

    Other: Ambient Heat

  • Experimental
    Propranolol, then Placebo, then Metoprolol

    Other: Ambient Heat

  • Experimental
    Propranolol, then Metoprolol, then Placebo

    Other: Ambient Heat

  • Experimental
    Metoprolol, then Placebo, then Propranolol

    Other: Ambient Heat

  • Experimental
    Metoprolol, then Propranolol, then Placebo

    Other: Ambient Heat

Interventions

  • OtherAmbient Heat

    Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.

06

What researchers measure

Primary outcomes

  1. Internal temperature

    The change in internal temperature to the 3-hour heat exposure will be measured.

    Time frame: Continuously throughout the 3-hour heat exposure.

  2. Whole body sweat rate

    Whole body sweat rate will be measured via changes in pre/post nude body mass.

    Time frame: Nude body mass will be measured before and after the 3-hour heat exposure.

Secondary outcomes

  1. Heart rate

    Heart rate will be measured via electrocardiogram.

    Time frame: Continuously throughout the 3-hour heat exposure.

  2. Arterial blood pressure

    Systolic and diastolic arterial blood pressures will be measured via a brachial blood pressure cuff.

    Time frame: Continuously throughout the 3-hour heat exposure.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 3, 2024
StartActual
Oct 4, 2024
Primary completionEst.
Sep 30, 2027was Sep 2026
CompletionEst.
Sep 30, 2027was Sep 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Sep 30, 2027
Nov 20, 2026
Study completion
Sep 30, 2026→Sep 30, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Sep 30, 2026→Sep 30, 2027
    Study completion Sep 30, 2026→Sep 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06582680
Responsible party
Craig Crandall (Professor of Internal Medicine, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Sep 3, 2024
Start date
Oct 4, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Erin Harper, MS
Contact
erinharper@texashealth.org
214-345-4737
Courtney Kirby, RN
Contact
courtneykirby@texashealth.org
214-345-6502
Craig Crandall, PhD
principal investigator · Univ of Texas Southwestern Med Ctr

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion